February 24, 2020Biomedicine & PharmacotherapyOpen Access

Irigenin treatment alleviates doxorubicin (DOX)-induced cardiotoxicity by suppressing apoptosis, inflammation and oxidative stress via the increase of miR-425

View Full Paper

Ask AI

Bookmark

Why the study?

Clinical application of doxorubicin is largely limited by potential cardiotoxicity, and the effects of irigenin on this toxicity warranted exploration.

Does irigenin alleviate doxorubicin-induced cardiotoxicity in preclinical models?

Structured PICO

Does irigenin alleviate doxorubicin-induced cardiotoxicity in preclinical models?

Population

In vivo and in vitro models (HL-1 cells) of doxorubicin (DOX)-induced cardiotoxicity

Intervention

Irigenin (IR)

Comparator

Doxorubicin alone / untreated control

Outcome

Cardiotoxicity (fibrosis, cardiac dysfunction, injury, apoptosis, oxidative stress, and inflammation)surrogate

Irigenin protects against doxorubicin-induced cardiotoxicity in preclinical models by upregulating miR-425 and suppressing RIPK1.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Hypothesis-generating for irigenin in doxorubicin cardiotoxicity; prospective trials needed before clinical adoption.

Cite This Study

Guo et al. (2020) studied this question.

synapsesocial.com/papers/6a821cbba8461dff0846bf56 https://doi.org/10.1016/j.biopha.2019.109784

View Full Paper

Ask AI

Bookmark

Irigenin treatment alleviates doxorubicin (DOX)-induced cardiotoxicity by suppressing apoptosis, inflammation and oxidative stress via the increase of miR-425

Structured PICO

Discussion

Implication

Cite This Study

Irigenin treatment alleviates doxorubicin (DOX)-induced cardiotoxicity by suppressing apoptosis, inflammation and oxidative stress via the increase of miR-425

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider